IRulya Therapeutics Posts $27.7M Q3 Loss, $105M Runway to 2028

IRulya Therapeutics Inc. (Nasdaq: IRLA) reported a net loss of $27.7 million, or $2.31 per basic and diluted share, for the third quarter ended September 30, 2026, against a $13.4 million loss a year earlier, the clinical-stage biopharmaceutical company announced on November 13, 2026. Cash, cash equivalents and investments stood at $105.2 million, which the company said should fund operations through the end of 2028. The company, formerly Quince Therapeutics, began trading on the Nasdaq Capital Market under the ticker IRLA on October 12, 2026.

Context — Why the Q3 2026 Numbers Matter Now

The quarter marks the first full reporting period after the company's rebrand and the conversion of its Series C preferred stock. Stockholders approved the conversion on October 6, 2026, and the Series C preferred converted to common on October 9, 2026, subject to beneficial ownership limits set by each holder. Outstanding common stock reached 10,841,470 as of November 5, 2026, up from 1,017,063 shares recorded on September 30, 2026.

That share-count jump explains the collapse in per-share loss. The $2.31 basic and diluted loss per share for Q3 2026 compares with $49.83 a year earlier. The report notes prior-period figures were adjusted for a 1-for-10 reverse stock split effected April 10, 2026 and a 1-for-20 reverse split effected June 29, 2026.

What triggered the reporting event is the corporate reset: a new name, a new leadership team, and a narrowed pipeline. The company appointed Brigette Roberts, M.D., as Chief Executive Officer, John Militello, CPA, as Chief Financial Officer, and Keith Fandrick, Ph.D., as Chief Operating Officer. Four new directors joined the board.

IRulya is now a single-asset story built around LAM-001, an inhaled dry-powder formulation of rapamycin targeting the mTOR pathway in the lungs. The company's thesis is that direct pulmonary delivery can cut systemic exposure and side effects relative to oral dosing. That reframing matters because the prior Quince program is being wound down, and the cost base is shifting accordingly.

The macro backdrop is secondary here. For a pre-revenue biotech, the binding constraint is the cash runway and the clinical calendar, not the rate cycle. The company said its $105.2 million position covers operations through the end of 2028, which spans three separate Phase 2 readouts.

Data — What the Numbers Show

R&D expense fell to $5.9 million in Q3 2026 from $8.1 million a year earlier. The company attributed the drop primarily to a $6.9 million decrease in eDSP program costs from winding down the Quince program, partly offset by a $3.8 million increase in LAM-001 costs tied to PH-ILD Phase 2b start-up.

G&A expense rose to $9.0 million from $3.3 million. The company cited $3.0 million in post-acquisition professional fees and a $2.7 million rise in personnel costs, primarily one-time severance and retention bonuses for terminated employees.

Metric	Q3 2026	Q3 2025
Net loss	$27.7M	$13.4M
R&D expense	$5.9M	$8.1M
G&A expense	$9.0M	$3.3M
Loss per share	$2.31	$49.83

On the balance sheet, total assets were $106.5 million against $28.4 million in liabilities at September 30, 2026. Series C redeemable convertible preferred stock stood at $143.8 million. Total stockholders' deficit was $65.7 million, versus a $35.7 million deficit at December 31, 2025.

Cash rose to $105.2 million from $17.8 million at December 31, 2025. For the nine months ended September 30, 2026, the net loss was $67.3 million, or $10.79 per share, compared with $44.5 million, or $184.60 per share, a year earlier. The nine-month period included a $67.8 million intangible asset impairment charge and $59.0 million in acquired in-process R&D.

The report does not disclose a peer comparison or a sector benchmark, so no external read-across is offered here.

Analysis — What It Means for IRLA and Biotech Investors

The second-order effect of this quarter is a cleaner cost structure pointed at one molecule. Wind-down of the eDSP program removed roughly $6.9 million of quarterly R&D, and the new LAM-001 spend is front-loaded study start-up rather than maintenance. If the PH-ILD Phase 2b trial moves from start-up into steady-state enrollment, the quarterly R&D line becomes the number to watch.

The G&A spike is a one-time integration cost, not a run-rate. Severance and retention bonuses for terminated employees do not recur, and post-acquisition professional fees typically roll off after the first full reporting cycle. The risk is that the company's own guidance of a runway to end-2028 assumes those costs normalize.

A second risk sits in the share structure. The Series C conversion lifted outstanding shares from about 1.0 million to 10.8 million, and the $143.8 million preferred balance still sits above a $65.7 million stockholders' deficit. Dilution math for existing holders depends on how remaining beneficial ownership limitations are released, and the company did not disclose the terms of those limits.

Positioning in clinical-stage pulmonary biotech is typically event-driven. Holders of IRLA are effectively long a binary BOS dataset due in the first quarter of 2027, with PH-ILD as a later option. Funds that avoid pre-data biotech will stay out until that readout lands.

A counter-argument: the $105.2 million runway is stated in company guidance, not audited forward projections. Clinical trial costs can exceed budgets, and a single enrollment slowdown or protocol amendment can shorten the runway materially.

Outlook — What to Watch Next

Three dated catalysts sit on the calendar. BOS Phase 2 data is anticipated in the first quarter of 2027. The company plans to initiate a Phase 2 study in sarcoidosis-associated pulmonary hypertension in the fourth quarter of 2026, with data anticipated in the fourth quarter of 2028. PH-ILD Phase 2b data is anticipated in the first quarter of 2028.

Investors will also watch the quarterly R&D and G&A lines to see whether the one-time charges roll off as expected, and whether the cash balance declines in line with the stated runway. The report gives no price levels, moving averages, or valuation multiples, so none are cited here.

On the clinical side, the BOS trial (NCT06018766) is fully enrolled, which removes enrollment risk from that readout. The PH-ILD trial (NCT05798923) remains ongoing. Any update on SAPH study initiation timing is the nearest-term disclosure to track.

Frequently Asked Questions

Why did IRulya's loss per share fall from $49.83 to $2.31?

The drop reflects a much larger share count, not an improvement in profitability. Outstanding common stock rose from 1,017,063 shares at September 30, 2026 to 10,841,470 as of November 5, 2026 after the Series C preferred conversion. The report also notes prior-period per-share figures were restated for two reverse stock splits, a 1-for-10 in April 2026 and a 1-for-20 in June 2026.

What does the $105.2 million cash position actually cover?

The company said the balance should fund operations through the end of 2028. That window spans the BOS Phase 2 readout expected in the first quarter of 2027, the SAPH Phase 2 study the company plans to start in the fourth quarter of 2026, and the PH-ILD Phase 2b readout anticipated in the first quarter of 2028. It does not extend beyond those events.

What is LAM-001 and which diseases is it being tested in?

LAM-001 is a once-daily dry-powder inhaled formulation of rapamycin, designed to deliver the drug to the lungs while limiting systemic exposure. IRulya is developing it in three indications: bronchiolitis obliterans syndrome post lung transplant, pulmonary hypertension associated with interstitial lung disease, and sarcoidosis-associated pulmonary hypertension. The company describes it as potentially first in class in the inhaled mTOR approach.

Bottom Line

IRulya has funded itself to end-2028, but the entire equity story now rides on a single BOS dataset due in early 2027.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.